Cellectis BioResearch, a Subsidiary of Cellectis S.A., Announces the Market Launch of a First Revolutionary Research Kit

Biocitech, life sciences park - The biotech company Cellectis BioResearch (a subsidiary of Cellectis S.A. (Alternext: ALCLS)) today announced the market launch of a research kit for producing stable cell clones using gene targeting in just 4 weeks. The first p10^® class’ product is aimed at life science researchers worldwide and is available for immediate purchase via the company's web site at www.cellectis-bioresearch.com.

Conference call today at 3:00 pm CET (2:00 pm UK – 9:00 EST)

Please dial: +33 (0) 1 72 13 76 84

Cellectis BioResearch will follow up this initial hamster cell kit by rolling out the product range to other species - notably including mouse and human cells.

"The p10.3^® CHO kit is the result of 5 years of development work", stated Dr. André Choulika, Chairman of Cellectis BioResearch. "The use of meganucleases is revolutionizing targeted integration. Creating stable, targeted clones used to require between 6 and 12 months of cumbersome and unpredictable work. Our product performs this operation successfully in only 4 weeks".

"This first product is targeting a potential market of several million experiments a year”, added Marc Le Bozec, Managing Director of Cellectis BioResearch. "We are seeking to win a market share of a few percent within the mid-term and are developing a portfolio of 25 products in order to achieve that goal".

Cellectis BioResearch was incorporated in June 2008 and currently has around ten staff. It is developing avant-garde products for the generation of stable cell clones incorporating a single copy of a gene of interest at a predetermined genomic address thanks to the use of meganuclease¹ technology: some kits will include modified cells whereas others will feature only a meganuclease targeting an address in a genome of interest such as the human genome.

About Cellectis S.A.

Cellectis SA (www.cellectis.com) is a world leader in genome engineering and genome surgery. The company focuses on developing and producing custom meganucleases for use in vivo genome surgery addressing the therapeutic, agrifood, biomanufacturing and research sectors. Worldwide, Cellectis has entered into more than 50 agreements with major players in the pharma, biotech and agribiotech industries and has over 20 collaborations with academic research groups. Since its incorporation, Cellectis has raised over €50 million in both equity operations and public financing and is listed on the NYSE-Euronext Alternext market (ticker code: ALCLS). For more information on Cellectis, visit our website: www.cellectis.com

Disclaimer - This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company’s objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company’s management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company’s products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company’s prospectus prepared in connection with its IPO and on which the French Autorité des marchés financiers ("AMF”) granted its visa n° 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

¹ meganuclease: a protein molecule which can cut DNA at a very specific site on a chromosome.